Spyridoula Maraka
Concepts (244)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypothyroidism | 22 | 2024 | 54 | 9.400 |
Why?
| Thyroxine | 24 | 2024 | 47 | 6.990 |
Why?
| Pregnancy Complications | 13 | 2024 | 382 | 5.240 |
Why?
| Thyrotropin | 15 | 2024 | 47 | 2.480 |
Why?
| Thyroid Gland | 8 | 2022 | 73 | 1.710 |
Why?
| Diabetes Mellitus, Type 2 | 8 | 2022 | 467 | 1.680 |
Why?
| Asymptomatic Diseases | 4 | 2021 | 36 | 1.630 |
Why?
| Thyroid Nodule | 9 | 2023 | 31 | 1.500 |
Why?
| Abortion, Spontaneous | 4 | 2021 | 16 | 1.460 |
Why?
| Thyroid Diseases | 4 | 2024 | 25 | 1.440 |
Why?
| Thyroid Neoplasms | 9 | 2023 | 109 | 1.360 |
Why?
| Pre-Eclampsia | 2 | 2022 | 55 | 1.310 |
Why?
| Pregnancy | 17 | 2024 | 2584 | 1.250 |
Why?
| Hormone Replacement Therapy | 4 | 2024 | 27 | 1.080 |
Why?
| Humans | 78 | 2024 | 49827 | 1.080 |
Why?
| Tachycardia | 2 | 2015 | 29 | 1.040 |
Why?
| Bone Density Conservation Agents | 2 | 2015 | 77 | 0.990 |
Why?
| Thyroid Function Tests | 7 | 2024 | 24 | 0.980 |
Why?
| Diphosphonates | 2 | 2015 | 90 | 0.980 |
Why?
| Osteoporosis | 3 | 2017 | 146 | 0.970 |
Why?
| Multiple Endocrine Neoplasia Type 1 | 2 | 2022 | 4 | 0.960 |
Why?
| Cardiovascular Diseases | 3 | 2022 | 440 | 0.930 |
Why?
| Female | 42 | 2024 | 26329 | 0.910 |
Why?
| Adult | 31 | 2024 | 13160 | 0.840 |
Why?
| Hyperthyroidism | 1 | 2022 | 27 | 0.820 |
Why?
| Neuroendocrine Tumors | 1 | 2022 | 23 | 0.810 |
Why?
| Hypertension | 3 | 2022 | 532 | 0.810 |
Why?
| Hypertension, Pregnancy-Induced | 1 | 2022 | 15 | 0.810 |
Why?
| Insulin | 5 | 2022 | 457 | 0.790 |
Why?
| Electronic Health Records | 1 | 2023 | 205 | 0.760 |
Why?
| Transsexualism | 2 | 2017 | 8 | 0.760 |
Why?
| Gonadal Steroid Hormones | 2 | 2017 | 42 | 0.740 |
Why?
| Hypoglycemic Agents | 6 | 2022 | 166 | 0.740 |
Why?
| Iodine | 1 | 2020 | 10 | 0.730 |
Why?
| Suicidal Ideation | 1 | 2021 | 96 | 0.730 |
Why?
| Aircraft | 1 | 2020 | 9 | 0.720 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2022 | 488 | 0.710 |
Why?
| Infant Mortality | 1 | 2020 | 61 | 0.700 |
Why?
| Diabetes, Gestational | 2 | 2021 | 53 | 0.700 |
Why?
| Robotics | 1 | 2020 | 44 | 0.690 |
Why?
| Thyroid Hormones | 3 | 2022 | 18 | 0.680 |
Why?
| Pancreatic Neoplasms | 1 | 2022 | 213 | 0.670 |
Why?
| Malnutrition | 1 | 2020 | 87 | 0.660 |
Why?
| Graves Disease | 4 | 2022 | 18 | 0.650 |
Why?
| Triiodothyronine | 4 | 2022 | 29 | 0.640 |
Why?
| Premature Birth | 3 | 2021 | 147 | 0.620 |
Why?
| Rural Health Services | 1 | 2020 | 164 | 0.610 |
Why?
| Pregnancy Outcome | 5 | 2022 | 237 | 0.590 |
Why?
| Endocrinology | 3 | 2022 | 10 | 0.550 |
Why?
| Fetal Growth Retardation | 1 | 2016 | 41 | 0.540 |
Why?
| Treatment Outcome | 12 | 2022 | 5138 | 0.540 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2020 | 357 | 0.530 |
Why?
| Bone Density | 4 | 2017 | 379 | 0.470 |
Why?
| Retrospective Studies | 16 | 2024 | 6117 | 0.460 |
Why?
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2013 | 4 | 0.450 |
Why?
| Teratoma | 1 | 2013 | 25 | 0.450 |
Why?
| Middle Aged | 21 | 2024 | 11997 | 0.430 |
Why?
| Adrenal Gland Neoplasms | 3 | 2017 | 51 | 0.420 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 36 | 0.420 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2015 | 197 | 0.410 |
Why?
| Male | 24 | 2024 | 25093 | 0.390 |
Why?
| Blood Glucose | 4 | 2021 | 432 | 0.380 |
Why?
| Iodide Peroxidase | 4 | 2024 | 5 | 0.380 |
Why?
| Antithyroid Agents | 3 | 2022 | 7 | 0.370 |
Why?
| Prescription Drugs | 2 | 2021 | 38 | 0.370 |
Why?
| Mammaplasty | 2 | 2021 | 42 | 0.370 |
Why?
| Ovarian Neoplasms | 1 | 2013 | 448 | 0.330 |
Why?
| Free Tissue Flaps | 2 | 2021 | 61 | 0.320 |
Why?
| Myocardial Infarction | 2 | 2022 | 382 | 0.300 |
Why?
| Autoimmunity | 2 | 2024 | 35 | 0.290 |
Why?
| Young Adult | 7 | 2024 | 3936 | 0.280 |
Why?
| Hyperparathyroidism, Primary | 2 | 2016 | 36 | 0.270 |
Why?
| Parathyroidectomy | 2 | 2016 | 46 | 0.270 |
Why?
| Inappropriate Prescribing | 2 | 2016 | 18 | 0.270 |
Why?
| Decision Making | 3 | 2021 | 262 | 0.270 |
Why?
| Thyroidectomy | 3 | 2024 | 59 | 0.260 |
Why?
| Risk Factors | 5 | 2024 | 3619 | 0.260 |
Why?
| United States | 7 | 2024 | 4838 | 0.260 |
Why?
| Risk Assessment | 3 | 2021 | 1262 | 0.250 |
Why?
| Thyroiditis, Autoimmune | 1 | 2024 | 2 | 0.240 |
Why?
| Biopsy, Fine-Needle | 4 | 2018 | 103 | 0.230 |
Why?
| Adolescent | 6 | 2024 | 6340 | 0.230 |
Why?
| Peripheral Vascular Diseases | 1 | 2022 | 21 | 0.210 |
Why?
| Vasoactive Intestinal Peptide | 1 | 2022 | 17 | 0.210 |
Why?
| Prospective Studies | 3 | 2024 | 2344 | 0.200 |
Why?
| Aged | 13 | 2022 | 9272 | 0.200 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1541 | 0.200 |
Why?
| Chorionic Gonadotropin | 1 | 2021 | 18 | 0.190 |
Why?
| Abdominoplasty | 1 | 2021 | 3 | 0.190 |
Why?
| Abdominal Wall | 1 | 2021 | 12 | 0.190 |
Why?
| Metformin | 1 | 2022 | 64 | 0.190 |
Why?
| Negative-Pressure Wound Therapy | 1 | 2020 | 11 | 0.190 |
Why?
| Ultrasonography, Interventional | 3 | 2016 | 135 | 0.190 |
Why?
| Transforming Growth Factor beta | 1 | 2021 | 144 | 0.180 |
Why?
| Thyroid (USP) | 1 | 2020 | 1 | 0.180 |
Why?
| Diabetes Mellitus | 2 | 2022 | 283 | 0.180 |
Why?
| Islands | 1 | 2020 | 2 | 0.180 |
Why?
| Electronic Prescribing | 1 | 2020 | 4 | 0.180 |
Why?
| Ireland | 1 | 2020 | 11 | 0.180 |
Why?
| Pheochromocytoma | 2 | 2017 | 35 | 0.180 |
Why?
| Patient Safety | 1 | 2021 | 101 | 0.180 |
Why?
| Iodine Radioisotopes | 1 | 2020 | 35 | 0.180 |
Why?
| Specimen Handling | 1 | 2020 | 54 | 0.180 |
Why?
| Patients | 1 | 2020 | 49 | 0.170 |
Why?
| Patient Participation | 2 | 2021 | 66 | 0.170 |
Why?
| Hypoglycemia | 1 | 2019 | 48 | 0.170 |
Why?
| Perception | 1 | 2020 | 116 | 0.170 |
Why?
| Patient Education as Topic | 1 | 2021 | 295 | 0.150 |
Why?
| Multiple Endocrine Neoplasia Type 2a | 1 | 2017 | 5 | 0.150 |
Why?
| Lower Extremity | 1 | 2018 | 88 | 0.150 |
Why?
| Databases, Factual | 2 | 2020 | 664 | 0.150 |
Why?
| Ischemia | 1 | 2018 | 152 | 0.150 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 33 | 0.150 |
Why?
| Stroke | 1 | 2022 | 492 | 0.140 |
Why?
| Follow-Up Studies | 3 | 2017 | 2179 | 0.140 |
Why?
| Time Factors | 2 | 2021 | 2912 | 0.140 |
Why?
| Telemedicine | 1 | 2022 | 443 | 0.140 |
Why?
| Apgar Score | 1 | 2016 | 35 | 0.140 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2017 | 191 | 0.140 |
Why?
| Bronchial Neoplasms | 1 | 2015 | 5 | 0.130 |
Why?
| Mutation | 1 | 2022 | 1293 | 0.130 |
Why?
| Carcinoid Tumor | 1 | 2015 | 14 | 0.130 |
Why?
| Physical Examination | 1 | 2016 | 90 | 0.130 |
Why?
| Infant, Low Birth Weight | 1 | 2016 | 62 | 0.130 |
Why?
| Infant | 2 | 2024 | 3551 | 0.130 |
Why?
| Thymus Neoplasms | 1 | 2015 | 17 | 0.130 |
Why?
| Sensitivity and Specificity | 4 | 2021 | 854 | 0.130 |
Why?
| Pancreas, Artificial | 1 | 2015 | 1 | 0.130 |
Why?
| Ultrasonography | 3 | 2022 | 436 | 0.130 |
Why?
| Adipocytes | 1 | 2016 | 121 | 0.130 |
Why?
| Stress, Physiological | 1 | 2016 | 170 | 0.130 |
Why?
| Multivariate Analysis | 1 | 2017 | 585 | 0.130 |
Why?
| Postoperative Complications | 2 | 2020 | 1000 | 0.130 |
Why?
| Computer Security | 1 | 2015 | 21 | 0.130 |
Why?
| Intensive Care Units, Neonatal | 1 | 2016 | 110 | 0.130 |
Why?
| Arkansas | 1 | 2021 | 1967 | 0.120 |
Why?
| Cell Transformation, Neoplastic | 1 | 2016 | 177 | 0.120 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1159 | 0.120 |
Why?
| Anthropometry | 1 | 2015 | 92 | 0.120 |
Why?
| Fractures, Bone | 1 | 2015 | 106 | 0.120 |
Why?
| Postoperative Period | 1 | 2015 | 172 | 0.120 |
Why?
| Bariatric Surgery | 1 | 2015 | 40 | 0.120 |
Why?
| Biopsy | 1 | 2016 | 582 | 0.120 |
Why?
| Early Detection of Cancer | 1 | 2015 | 165 | 0.120 |
Why?
| Logistic Models | 1 | 2017 | 891 | 0.120 |
Why?
| Quality of Life | 4 | 2022 | 833 | 0.110 |
Why?
| Case-Control Studies | 1 | 2016 | 1128 | 0.110 |
Why?
| Maternal Age | 2 | 2024 | 44 | 0.110 |
Why?
| White Coat Hypertension | 1 | 2012 | 1 | 0.110 |
Why?
| Time | 1 | 2012 | 25 | 0.110 |
Why?
| Body Weight | 1 | 2015 | 513 | 0.110 |
Why?
| Autoantibodies | 2 | 2024 | 116 | 0.110 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 448 | 0.100 |
Why?
| Circadian Rhythm | 1 | 2012 | 87 | 0.100 |
Why?
| Aged, 80 and over | 4 | 2022 | 3125 | 0.100 |
Why?
| Renal Insufficiency | 1 | 2012 | 109 | 0.100 |
Why?
| Risk | 1 | 2012 | 320 | 0.100 |
Why?
| Antihypertensive Agents | 1 | 2012 | 115 | 0.100 |
Why?
| Bone and Bones | 1 | 2015 | 468 | 0.100 |
Why?
| Glucose | 2 | 2022 | 340 | 0.090 |
Why?
| Body Mass Index | 2 | 2024 | 652 | 0.080 |
Why?
| Drug Utilization | 2 | 2021 | 78 | 0.080 |
Why?
| Image-Guided Biopsy | 2 | 2016 | 33 | 0.070 |
Why?
| Infant, Newborn | 2 | 2022 | 2744 | 0.060 |
Why?
| Cohort Studies | 2 | 2021 | 1422 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2017 | 904 | 0.060 |
Why?
| Policy | 1 | 2022 | 24 | 0.050 |
Why?
| Thyroglobulin | 1 | 2022 | 7 | 0.050 |
Why?
| Goals | 1 | 2022 | 40 | 0.050 |
Why?
| Immunization, Passive | 1 | 2022 | 29 | 0.050 |
Why?
| Odds Ratio | 1 | 2024 | 548 | 0.050 |
Why?
| Reference Values | 1 | 2022 | 310 | 0.050 |
Why?
| Counseling | 1 | 2023 | 133 | 0.050 |
Why?
| Androgens | 1 | 2022 | 69 | 0.050 |
Why?
| Insurance Claim Review | 1 | 2021 | 36 | 0.050 |
Why?
| Colombia | 1 | 2021 | 15 | 0.050 |
Why?
| Physician-Patient Relations | 1 | 2023 | 140 | 0.050 |
Why?
| Iron-Binding Proteins | 1 | 2021 | 2 | 0.050 |
Why?
| Evidence-Based Medicine | 1 | 2022 | 248 | 0.050 |
Why?
| Parity | 1 | 2021 | 50 | 0.050 |
Why?
| Glucose Tolerance Test | 1 | 2021 | 57 | 0.050 |
Why?
| Decision Support Techniques | 1 | 2021 | 70 | 0.050 |
Why?
| Ambulatory Care | 1 | 2022 | 222 | 0.050 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2021 | 48 | 0.050 |
Why?
| China | 1 | 2021 | 87 | 0.050 |
Why?
| Communication | 1 | 2023 | 244 | 0.050 |
Why?
| Medication Adherence | 1 | 2022 | 126 | 0.050 |
Why?
| Autoantigens | 1 | 2021 | 58 | 0.050 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 378 | 0.050 |
Why?
| Abdomen | 1 | 2020 | 79 | 0.050 |
Why?
| Linear Models | 1 | 2021 | 281 | 0.040 |
Why?
| Florida | 1 | 2020 | 58 | 0.040 |
Why?
| Educational Status | 1 | 2021 | 222 | 0.040 |
Why?
| Documentation | 1 | 2019 | 33 | 0.040 |
Why?
| Medicare | 1 | 2021 | 244 | 0.040 |
Why?
| Blood Pressure | 1 | 2022 | 514 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2021 | 220 | 0.040 |
Why?
| Oxygen | 1 | 2022 | 325 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 553 | 0.040 |
Why?
| Disease Management | 1 | 2020 | 174 | 0.040 |
Why?
| Optical Imaging | 1 | 2018 | 25 | 0.040 |
Why?
| Tibial Fractures | 1 | 2018 | 32 | 0.040 |
Why?
| Social Media | 1 | 2020 | 97 | 0.040 |
Why?
| Femur Neck | 1 | 2017 | 6 | 0.040 |
Why?
| Hospitalization | 1 | 2022 | 653 | 0.040 |
Why?
| Incidence | 1 | 2020 | 1003 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 175 | 0.040 |
Why?
| Osteomyelitis | 1 | 2018 | 126 | 0.040 |
Why?
| Hypocalcemia | 1 | 2016 | 8 | 0.040 |
Why?
| Recurrent Laryngeal Nerve Injuries | 1 | 2016 | 7 | 0.040 |
Why?
| Methimazole | 1 | 2016 | 1 | 0.040 |
Why?
| Lumbar Vertebrae | 1 | 2017 | 98 | 0.040 |
Why?
| 3T3-L1 Cells | 1 | 2016 | 13 | 0.040 |
Why?
| Caloric Restriction | 1 | 2016 | 34 | 0.030 |
Why?
| Hypercalcemia | 1 | 2016 | 33 | 0.030 |
Why?
| Health Literacy | 1 | 2018 | 129 | 0.030 |
Why?
| Primary Health Care | 1 | 2019 | 353 | 0.030 |
Why?
| Health Care Surveys | 1 | 2016 | 174 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 91 | 0.030 |
Why?
| Endpoint Determination | 1 | 2015 | 24 | 0.030 |
Why?
| Observer Variation | 1 | 2016 | 129 | 0.030 |
Why?
| Lipids | 1 | 2016 | 147 | 0.030 |
Why?
| Diagnostic Errors | 1 | 2016 | 63 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 231 | 0.030 |
Why?
| Uncertainty | 1 | 2015 | 45 | 0.030 |
Why?
| Madagascar | 1 | 2015 | 2 | 0.030 |
Why?
| Child, Preschool | 1 | 2024 | 3853 | 0.030 |
Why?
| Metabolomics | 1 | 2016 | 124 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1036 | 0.030 |
Why?
| Patient-Centered Care | 1 | 2016 | 128 | 0.030 |
Why?
| Insulin Resistance | 1 | 2016 | 264 | 0.030 |
Why?
| Referral and Consultation | 1 | 2015 | 287 | 0.030 |
Why?
| Proteins | 1 | 2016 | 341 | 0.030 |
Why?
| Proteomics | 1 | 2016 | 328 | 0.030 |
Why?
| Pilot Projects | 1 | 2015 | 699 | 0.030 |
Why?
| Registries | 1 | 2015 | 518 | 0.030 |
Why?
| Cells, Cultured | 1 | 2016 | 1571 | 0.030 |
Why?
| MicroRNAs | 1 | 2016 | 354 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2016 | 1806 | 0.020 |
Why?
| Prognosis | 1 | 2016 | 1952 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2015 | 1533 | 0.020 |
Why?
| Obesity | 1 | 2016 | 1113 | 0.020 |
Why?
| Mice | 1 | 2016 | 5720 | 0.020 |
Why?
| Animals | 1 | 2016 | 13150 | 0.010 |
Why?
|
|
Maraka's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|